Clinical Trial Update: Benefits of Trimetazidine in MASLD Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating trimetazidine in Metabolic Associated Fatty Liver Disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic-associated Fatty Liver Disease

Drugs mentioned

• Trimetazidine (trimetazidine)

Snippet

Sponsor: October 6 University | Conditions: Metabolic Associated Fatty Liver Disease | Phase 2 | Status: COMPLETED